IP Library Granted Patent US 11,034,647
Granted Patent B2
US 11,034,647 · App. 16/708,190 · Granted Jun 15, 2021

Histone acetyltransferase activators and uses thereof

Inventors: Yan Feng (Shanghai, CN); Mauro Fa (New York, NY); Ottavio Arancio (New York, NY); Shixian Deng (White Plains, NY); Donald W. Landry (New York, NY); Yitshak Francis (New York, NY)
Assignee: The Trustees of Columbia University in the City of New York
C07C235/64A61K49/00C07C235/56C07C237/40C07C323/42C07C323/44C07C323/60C07C323/67C07D213/75C07D213/82C07D239/52C07D333/38C12Q1/48C07C2601/08G01N2500/04G01N2800/2814
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,034,647
App. No.
16/708,190
Granted
Jun 15, 2021
Kind
B2
Abstract

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

Claims (12)

1. A method for treating cancer in a subject, the method comprising administering to a subject a therapeutic amount of a pharmaceutical composition comprising a compound having the following structure:

or a pharmaceutically acceptable salt or hydrate thereof.

2. The method of claim 1 , wherein the therapeutic amount is at least about 1 mg/kg body weight, at least about 2 mg/kg body weight, at least about 3 mg/kg body weight, at least about 4 mg/kg body weight, at least about 5 mg/kg body weight, at least about 6 mg/kg body weight, at least about 7 mg/kg body weight, at least about 8 mg/kg body weight, at least about 9 mg/kg body weight, at least about 10 mg/kg body weight, at least about 15 mg/kg body weight, at least about 20 mg/kg body weight, at least about 25 mg/kg body weight, at least about 30 mg/kg body weight, at least about 40 mg/kg body weight, at least about 50 mg/kg body weight, at least about 75 mg/kg body weight, or at least about 100 mg/kg body weight.

3. The method of claim 1 , wherein the cancer comprises B cell lymphoma, colon cancer, lung cancer, renal cancer, bladder cancer, T cell lymphoma, myeloma, leukemia, chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, hematopoietic neoplasias, thymoma, lymphoma, sarcoma, liver cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, uterine cancer, renal cell carcinoma, hepatoma, adenocarcinoma, breast cancer, pancreatic cancer, prostate cancer, head and neck carcinoma, thyroid carcinoma, soft tissue sarcoma, ovarian cancer, primary or metastatic melanoma, squamous cell carcinoma, basal cell carcinoma, brain cancer, angiosarcoma, hemangiosarcoma, bone sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, testicular cancer, cervical cancer, gastrointestinal cancer, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, Waldenstroom's macroglobulinemia, papillary adenocarcinomas, cystadenocarcinoma, bronchogenic carcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, lung carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, retinoblastoma, melanoma, neuroblastoma, small cell lung carcinoma, bladder carcinoma, multiple myeloma, or medullary carcinoma.

4. The method of claim 1 , wherein the compound increases histone acetylation.

5. The method of claim 4 , wherein histone acetylation comprises acetylation of histones H2B, H3, H4, or a combination thereof.

6. The method of claim 4 , wherein histone acetylation comprises acetylation of histone lysine residues H3K4, H3K9, H3K14, H4K5, H4K8, H4K12, H4K16, or a combination thereof.

7. The method of claim 3 , wherein the cancer is colon cancer, lung cancer, renal cancer, leukemia, CNS cancer, melanoma, ovarian cancer, breast cancer, or prostate cancer.

8. The method of claim 3 , wherein the cancer is colon cancer, renal cancer, T cell leukemia, myeloma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, renal cell carcinoma, adenocarcinoma, glioblastoma, breast carcinoma, prostate carcinoma, or lung carcinoma.

9. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is an acid addition salt thereof.

11. The method of claim 1 , wherein the compound is a hydrochloride salt thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 2, 2022
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061054/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2020
From: FRANCIS, YITSHAK; ARANCIO, OTTAVIO; LANDRY, DONALD W; FA, MAURO; FENG, YAN; DENG, SHIXIAN
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 051543/0429 →
Continuity (9)
Division 13493490 · Jun 11, 2012
Continuation In Part PCTUS2010059925 · Dec 10, 2010
Provisional Application 61539697 · Sep 27, 2011
Provisional Application 61363009 · Jul 9, 2010
Provisional Application 61354964 · Jun 15, 2010
Provisional Application 61355110 · Jun 15, 2010
Provisional Application 61317765 · Mar 26, 2010
Provisional Application 61285287 · Dec 10, 2009
Related Publication 20200115325A1 · Apr 16, 2020